Traditional methods for quantifying the activity of VEGF are based on the ability of anti-VEGF antibodies to inhibit the proliferation of cells expressing VEGFR receptors, following treatment with VEGF. These assays can take days, suffer from high variability and are difficult to validate.

In a recent paper, Lallemand and colleagues have used iLite® VEGF reporter-gene assays and ADCC assays from Svar Life Science to analyze samples from patients with ovarian cancer and glioblastoma that had been treated with bevacizumab.